blue cross blue shield glp-1 coverage 2025 to stop covering popular weight-loss drugs Why we are changing coverage
Description
doi: 10.3390/antiox8090388, 50
[DOI] [PubMed] [Google Scholar] 22.Fiorentino M, Bolignano D, Tesar V, Pisano A, Biesen WV, Tripepi G, et al
[DOI] [PubMed] [Google Scholar] 40.Drucker D.J
In animal models, GLP-1R agonists prevent capillary rarefaction and microvascular barrier dysfunction and reduce apoptosis and reactive oxygen species in microvascular endothelial cells, contributing to improved organ function and reduced progression of microvascular complications [162]
Patients can develop gastroparesiswhere the stomach stops movingand patients vomit frequently
The concept of treating two conditions (diabetes and obesity) with one shot is very appealing
